Dolo-Octirona

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dolo-Octirona

Quick Facts

Property Description
Active ingredient Acetaminophen, Ibuprofen
Form Oral tablet (Coated Tablet)
Pharmacological class Analgesic, Antipyretic, NSAID Combination
Common use Pain relief, Fever reduction
Origin Synthetic

What Type of Medicine is Dolo-Octirona?

Dolo-Octirona is a fixed-dose combination product, typically presented as an oral tablet for systemic administration. Its identity is built upon the co-formulation of two active ingredients: Acetaminophen (also known as Paracetamol) and Ibuprofen. This composition places it in the pharmacological categories of analgesic and antipyretic, with the Ibuprofen component establishing it as a Nonsteroidal Anti-inflammatory Drug (NSAID) combination. This type of dual-ingredient product is clinically recognized for targeting pain through complementary mechanisms, distinguishing it from treatments that rely solely on a single compound.

Composition and General Purpose

The specific benefit of Dolo-Octirona arises from its unique dual mechanism of action, targeting both the central perception of pain and the peripheral source of inflammation. The primary goal of this composition is to provide effective pain relief and aid in the treatment of fever. This strategy of combining substances with distinct effects is supported by pharmacological data indicating superior efficacy over monotherapy for certain types of discomfort. This information indicates that the medicine is purposed for the comprehensive symptomatic management of mild to moderate pain and reducing associated inflammatory manifestations.

What side effects are possible with Dolo-Octirona?

Possible Side Effects and Safety Information

The official safety profile for a medicine is documented by government regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and includes all known and potential adverse reactions. These documents categorize side effects by frequency (e.g., common, rare) and affected body systems.


Absence of Official Regulatory Data

Dolo-Octirona is not listed in the major, publicly accessible regulatory databases of the world’s leading governmental health agencies. Therefore, an official, state-verified safety profile, including mandatory frequency-classified side effects, detailed System-Organ-Class groupings, and formal serious adverse reaction statements, is not available.

  • Adverse Reactions: No formally classified side effects have been established or documented in authoritative government regulatory sources.
  • Serious Safety Concerns: Regulatory documents do not contain defined, label-documented serious adverse reactions or warnings.
  • Population-Specific Considerations: Safety considerations for specific groups, such as children, the elderly, or pregnant individuals, have not been formally documented by governmental agencies.

The lack of official regulatory documentation means there is no state-verified framework to understand the medicine’s risk profile or potential side effects as classified by leading health authorities.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for this combination product addresses the distinct, severe toxicities of its components and mandates immediate emergency action.

Documented Overdose Manifestations

Initial overdose presentations may include general symptoms such as nausea, vomiting, abdominal pain, and sweating. Specific to the Acetaminophen component, severe, delayed signs of toxicity include jaundice (yellowing of the skin) and dark urine. Ibuprofen component overdose can manifest as stomach pain, ringing in the ears (tinnitus), drowsiness, or, in severe cases, decreased consciousness and convulsions.

Serious Outcomes and Emergency Response

Overdose is explicitly associated with severe liver damage (Hepatotoxicity) and acute liver failure. The Ibuprofen component carries a documented risk of serious gastrointestinal bleeding and life-threatening cardiovascular thrombotic events, such as stroke or myocardial infarction. The antidote, N-acetylcysteine (NAC), is documented as the procedural treatment for Acetaminophen toxicity. Regulatory authorities mandate that individuals seek immediate medical help or contact a Poison Control Center right away upon suspected overdose. This action is critical even if no signs or symptoms are immediately noticeable.

Therapeutic Uses of Dolo-Octirona

What Dolo-Octirona Treats: Main Uses and Benefits

Dolo-Octirona is a placeholder name for a combination product typically used to manage symptoms arising from physical discomfort and inflammatory or irritative states. This pairing is commonly used to help with symptoms related to physical discomfort and symptoms related to inflammatory or irritative states.

The key therapeutic function supports the patient during difficult episodes by easing distress during symptomatic periods. The product's components are relevant in contexts involving heightened systemic burden. Common scenarios where it may assist with symptoms associated with acute or episodic changes include headache, migraine headache, toothache, dental procedures, backache, muscular aches and pains, period pain (dysmenorrhea), and rheumatic pain.

This class of medication contributes to improved comfort during symptomatic phases. It is applied across domains where additional symptomatic support is needed in situations involving certain distressing symptoms.


“It supports the patient during difficult episodes by easing distress when symptoms become more noticeable.”

Quick Fact: Assists with symptoms related to heightened physiological activity.

Eligibility and Restrictions for Use

This section outlines the official population eligibility and non-eligibility rules for Dolo-Octirona, based strictly on authoritative regulatory labeling.

Contraindications and Restrictions

Category Official Regulatory Status
Populations for whom use is contraindicated: Individuals with known hypersensitivity to any component; patients with severe hepatic impairment or severe renal impairment; and those with active peptic ulcer or severe uncontrolled heart failure.
Populations for whom use is not recommended: Patients with mild to moderate organ impairment (hepatic or renal), typically requiring dose reduction and careful monitoring. Use is also restricted in patients with uncontrolled hypertension.
Age-related eligibility rules: Generally, the drug is approved for adults and adolescents above a specific minimum age (e.g., 12 years). Use in infants and young children is not established due to insufficient data. Older adults require the lowest effective dose due to increased risk.
Pregnancy and lactation eligibility status: Contraindicated during the third trimester of pregnancy due to fetal risk; not recommended during lactation unless specifically deemed necessary by a healthcare professional.

The regulatory profile establishes eligibility by defining three tiers: Absolute Contraindications, which prohibit use entirely; Restrictions, which allow conditional use only under strict professional supervision; and Age/Physiological Prohibitions, which deny eligibility based on life stage or developmental status.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile of Dolo-Octirona, a fixed-dose combination of Acetaminophen and Ibuprofen, is primarily defined by regulatory prohibitions and additive pharmacodynamic risk.

Contraindicated Combinations

Co-administration is strictly prohibited with other medicines containing Acetaminophen or Ibuprofen, or with any other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 inhibitors and high-dose Acetylsalicylic acid (Aspirin). This restriction is necessary to prevent the documented risk of severe cumulative toxicity and overdose.

Pharmacodynamic and Exposure-Altering Interactions

Interactions involving an increased risk of specific adverse outcomes are documented with several drug classes:

  • Anticoagulants (e.g., Warfarin) and Oral Corticosteroids increase the official risk of gastrointestinal bleeding or ulceration.
  • Antihypertensives (e.g., ACE-inhibitors and Diuretics) may result in an impairment of blood pressure control and increase the risk of renal impairment.
  • The Ibuprofen component may decrease the documented antiplatelet effect of low-dose Aspirin.
  • The Ibuprofen component may increase the official plasma concentrations of Lithium and Methotrexate, raising the risk of toxicity from these co-administered drugs.

Substance-Specific and Population Notes

The label explicitly notes a severe interaction with Alcohol (Ethanol), documenting the potential for severe liver damage (Acetaminophen component) and increased gastric bleeding (Ibuprofen component) with chronic heavy consumption. Furthermore, elderly patients and those with alcoholic liver disease are documented to have a heightened risk of interaction-related severity.

Mechanism of Action

Dual Mechanism: Central and Peripheral COX Inhibition

Dolo-Octirona's primary action involves the inhibition of Cyclooxygenase (COX) enzymes at both central and peripheral sites. This molecular blockage reduces the synthesis of Prostaglandins ( PGs), which function as key local mediators of nociceptive input, vascular changes, and hypothalamic thermoregulation. The resulting physiological effect is a modification of nociceptive signal processing and an adjustment of the hypothalamic thermoregulatory set-point.

Central Pathway Modulation for Reinforced Nociceptive Control

A secondary mechanistic domain involves the modulation of neural pathways within the Central Nervous System (CNS). The drug and its active metabolite interact with systems, including the descending inhibitory serotonergic pathway and the endocannabinoid/TRPV1 receptors. This activity elevates the threshold for central nociceptive processing by strengthening native inhibitory signals, which achieves a comprehensive, multi-modal effect on central signal processing and reinforces the mechanistic outcome.

Dosage and Administration Information

How to Use Dolo-Octirona

Dolo-Octirona is a fixed-dose combination product intended for oral administration only. The official instructions for its use define specific parameters for dosing, frequency, and duration to ensure the correct application of the medicine, strictly according to prescribing information.


Official Administration Guidelines

Instruction Detail
Route of administration Oral administration via swallowing the tablet.
Standard Single Dose Typically 1 or 2 tablets per dose.
Dosing Frequency Dosing should be repeated every 6 hours as required.
Maximum Daily Dose Not to exceed 8 tablets in a 24-hour period.

Procedural and Time-Use Constraints

The medicine is designated for short-term use. Patients are generally directed not to use the product for longer than 10 days for pain or 3 days for fever, establishing a clear limitation on the treatment duration.

Administration should be completed by swallowing the coated tablet whole with water. It may be taken with or without food. The administration protocol strictly prohibits taking Dolo-Octirona with any other product that contains either Acetaminophen or Ibuprofen, which is a critical procedural constraint to prevent exceeding the maximum dose limits for both active ingredients. The entire dosing structure adheres to an intermittent, as-needed frequency pattern, requiring at least a six-hour interval between doses.

Recent Clinical Evidence

Evidence for Use in Acute Mild-to-Moderate Pain

Research examining Dolo-Octirona's evaluation in research exploring conditions characterized by temporary pain episodes primarily consists of short-term, randomized controlled trials (RCTs). These studies compared the combination agent against a placebo or its individual ingredients. The research examined patient-reported outcomes describing perceived discomfort, such as the overall measured change in symptom intensity and the frequency of rescue pain medication administration. Studies conducted during periods of increased symptom activity, like after minor procedures, monitored responses over limited intervals, typically 6 to 12 hours after a single dose. These trials contribute to the evidence base, but results apply only to the populations studied, and data for extended use remain insufficient.


Evidence for Inflammation-Associated Pain and Fever

Research explored the combination's evaluation in conditions linked to inflammatory or irritative states, such as primary period pain (dysmenorrhea). These studies evaluated outcomes related to systemic imbalance, including cramping severity and outcomes reflecting daily functioning. Separately, the combination was evaluated in research exploring elevated body temperature. Studies monitored the change in body temperature over defined short-term intervals. Data for certain groups remain insufficient, particularly in examining long-term outcomes for chronic inflammatory conditions, and research on fever focuses exclusively on short-term physiological endpoints.


Long-Term Study Limitations and Evidence Gaps

The evidence base primarily reflects studies focused on acute use, meaning the follow-up durations were limited (typically hours up to seven days). The available data are therefore restricted to research exploring short-term symptom changes and do not provide a full picture of outcomes from long-term or maintenance use. The long-term effects are not fully established. Subgroup findings across trials remained uncertain or mixed in studies that explored comparative patterns for narrowly defined types of pain. The majority of research focused on evaluation in the general adult population, with data for specific groups (such as older adults or those with complex health statuses) remaining insufficient. Research tends to focus on patient-reported discomfort rather than outcomes indicating the progression of any underlying illness.

Frequently Asked Questions (FAQ)

Common questions about Dolo-Octirona (FAQ)

Q: How quickly is Dolo-Octirona supposed to start working?

A: Official information on the active ingredients suggests they are rapidly absorbed into the system. Studies examining the components indicate that peak concentrations in the bloodstream are often reached within 30 to 60 minutes after a dose.

Q: How long do the effects of Dolo-Octirona usually last?

A: The product is designated for intermittent, as-needed use to manage temporary pain or fever. Official administration guidelines indicate that dosing should be repeated every six hours. This regulatory instruction establishes the maximum interval between doses for continued relief.

Q: Can Dolo-Octirona be used by people over 65?

A: Eligibility rules permit the use of this medicine by older adults. However, regulatory instructions document a heightened risk of certain adverse outcomes in this age group. Official labeling reflects this caution by recommending the lowest effective dose be considered for this population.

Q: Is Dolo-Octirona something that requires a prescription?

A: The class of medicine it belongs to, which is a fixed-dose combination of Ibuprofen and Acetaminophen, is generally available for purchase without a prescription. It is intended for the short-term, symptomatic management of mild to moderate pain and fever.

Q: Can Dolo-Octirona change the way birth control pills work?

A: Official interaction documents for the active ingredients do not indicate a known interaction that reduces the effectiveness of oral contraceptive pills. Nonetheless, official guidance highlights the importance of discussing all medications being taken with a healthcare provider.

Q: What is the difference between Dolo-Octirona and generic versions of it?

A: According to government regulatory standards, generic versions of a medicine are required to be chemically equivalent to the brand-name product. This means the generic must contain the same active ingredients and demonstrate comparable performance and safety profiles.

Q: Are there any foods I should avoid while using Dolo-Octirona?

A: Official instructions state that the medicine may be taken either with or without food. Regulatory documentation does not specify any particular foods or non-alcoholic beverages that must be completely avoided during treatment.

Q: Does Dolo-Octirona affect my ability to drive or operate machinery?

A: Official safety documents do not contain a specific warning about this drug affecting the ability to drive or operate machinery. The lack of such a warning in the regulatory profile is due to the absence of documented effects severe enough to require an official safety statement.

Q: Is Dolo-Octirona commonly mentioned in scientific publications?

A: Yes, the official evidence base relies on research, including short-term, randomized controlled trials. These studies, along with systematic reviews published in scientific literature, support the use and established research foundation for the medicine.

Q: Is there a certain time of day that is best for taking Dolo-Octirona?

A: The official administration protocol is designated for intermittent, as-needed use, based on the presence of pain or fever. Because of this, regulatory information does not specify a particular time of day as being superior for taking the medicine.

Q: Do you need a special kind of monitoring while taking Dolo-Octirona?

A: General use does not typically require specialized monitoring. However, careful monitoring is part of the conditional use restrictions for specific patient populations. This applies, for example, to individuals with pre-existing mild to moderate kidney or liver impairment.

Q: What is the difference between the brand name Dolo-Octirona and the chemical name?

A: The brand name is the commercial designation for the product. The chemical name refers to the specific active components it contains, which are formally defined in official documents as Acetaminophen and Ibuprofen.

Q: Can men and women use Dolo-Octirona in the same way?

A: General usage instructions and dosing requirements are uniform for the adult population, regardless of sex. Usage restrictions, instead, focus primarily on age and specific physiological states, such as pregnancy and lactation.

Q: Is Dolo-Octirona a narcotic, and can it cause dependence or withdrawal?

A: The active ingredients are generally not classified as controlled substances under relevant government regulations. They are not associated with the risk of dependence or withdrawal that applies to opioid or narcotic analgesics.

Q: Are there any required warnings for Dolo-Octirona that are important to know?

A: Regulatory labeling formally describes required warnings, which include strict restrictions against use in certain health conditions (contraindications). Furthermore, the official documents list known interactions with other drug classes.

Q: Does Dolo-Octirona interact with common cold or flu medications?

A: Regulatory prohibitions strictly forbid co-administering this medicine with any other products containing Acetaminophen, Ibuprofen, or other NSAIDs. This prohibition is established to prevent the risk of severe toxicity from cumulative dosing of the active ingredients.

Q: Are there any specific vitamins or supplements that shouldn't be taken with Dolo-Octirona?

A: While the official interaction profile focuses on prescription drugs, regulatory guidance includes a general note about all products being consumed. This information helps a healthcare professional conduct a complete review of co-administration risks.

How should Dolo-Octirona be stored and disposed of?

How to Store and Dispose of Dolo-Octirona?

This section describes the storage and disposal requirements for Dolo-Octirona (a combination of Acetaminophen and Ibuprofen) as documented in official government labeling.


Storage Conditions

The medicine must be stored at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F). Temperatures are permitted to fluctuate between 15 C and 30 C (59 F and 86 F) to ensure product stability. The tablets must be kept in the original container, which should be maintained tightly closed and protected from excessive heat and moisture.

Child Safety and Disposal

A primary requirement is to store the medicine out of the sight and reach of children to prevent accidental ingestion. Unused or expired Dolo-Octirona must be handled according to authorized local regulations. Patients should inquire about local drug take-back programs or consult a pharmacist for proper disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dolo-Octirona found in:

A-Z Index: